Microvast Holdings announces departure of chief financial officer
Investing.com -- Anixa Biosciences Inc (NASDAQ:ANIX) stock climbed 4.2% following the announcement that the Canadian Intellectual Property Office has issued a Notice of Allowance for a new patent related to its breast cancer vaccine technology.
The patent, which Anixa exclusively licensed from Cleveland Clinic, provides composition-of-matter protection for the company’s immunogenic approach to breast cancer prevention and treatment in Canada. This development expands Anixa’s international intellectual property portfolio, complementing existing patents in the United States and other global jurisdictions.
"This newly allowed patent further illustrates the international recognition of the novelty and potential of our breast cancer vaccine," said Dr. Amit Kumar, Chairman and CEO of Anixa Biosciences. "As we continue advancing clinical development in the U.S., this allowance further strengthens our ability to pursue strategic global opportunities in regions with a high burden of breast cancer."
The company’s vaccine technology targets human α-lactalbumin, a protein associated with lactation that is abnormally expressed in certain breast cancers. This "retired" protein strategy aims to prime the immune system to prevent tumor formation while avoiding damage to normal tissue.
Breast cancer represents approximately 25% of all new cancer cases in women in Canada and 13% of female cancer deaths annually. Currently, there is no approved vaccine for breast cancer prevention, highlighting a significant unmet medical need that Anixa’s technology aims to address.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.